GlassScriptPhysician profile
Hannah Scherba
NPI 1245862085
$2,050.09
in general payments reported to CMS, 2019-2025
18 companies · $63.06 in 2025
The $63.06 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $525 · 2022: $944 · 2023: $126 · 2024: $392 · 2025: $63.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $581.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $880.06 | 2021-2024 | |
| Harmony Biosciences LLC | $206.53 | 2021 | |
| Idorsia Pharmaceuticals US INC | $121.30 | 2022 | |
| Ironshore Pharmaceuticals INC. | $116.83 | 2023-2024 | Jornay Pm |
| Optinose US, INC. | $108.73 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $99.99 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.02 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $72.52 | 2024 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Glaxosmithkline, LLC. | $67.78 | 2021-2022 | |
| Smith+Nephew, INC. | $64.37 | 2023-2024 | Oasis, Acticoat 4" X 4" |
| Collegium Pharmaceutical, INC. | $43.55 | 2025 | Jornay Pm |
| Solventum Corporation | $39.25 | 2024 | V.A.C. Veraflo, Prevena |
| Aytu Biopharma, INC. | $35.81 | 2024-2025 | Karbinal |
| Kci USA, INC. | $30.60 | 2023 | Prevena, V.A.C. Veraflo Cleanse Choice, V.A.C. Dermatac |
| Phadia US INC. | $26.01 | 2021-2024 | Immunocap |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $20.10 | 2023 | Ycanth |
| Kaleo, INC. | $19.98 | 2023 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $19.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Scherba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.